EA200900388A1 - Бензоксазолы и оксазолопиридины, применимые в качестве ингибиторов киназ janus - Google Patents

Бензоксазолы и оксазолопиридины, применимые в качестве ингибиторов киназ janus

Info

Publication number
EA200900388A1
EA200900388A1 EA200900388A EA200900388A EA200900388A1 EA 200900388 A1 EA200900388 A1 EA 200900388A1 EA 200900388 A EA200900388 A EA 200900388A EA 200900388 A EA200900388 A EA 200900388A EA 200900388 A1 EA200900388 A1 EA 200900388A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
compounds
treating
treatment
oxazozolypiridines
Prior art date
Application number
EA200900388A
Other languages
English (en)
Inventor
Марк Гершпахер
Паскаль Фюре
Эрик Вангревелень
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37717673&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200900388(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA200900388A1 publication Critical patent/EA200900388A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings

Abstract

В заявке описаны 2,7-дизамещенные бензоксазолы и 2,4-дизамещенные оксазоло[5,4-с]пиридины формулы I, приведенной ниже, а также их соли, способы их получения, их применение в способе лечения организма человека или животного, эти соединения, предназначенные для применения для лечения (включая профилактику) организма животного, предпочтительно человека (предпочтительно пролиферативного заболевания), их применение - по отдельности или в комбинации с одним или большим количеством других фармацевтически активных соединений - для лечения, предпочтительно опосредуемого протеинтирозинкиназой заболевания (такого как опухолевое заболевание) или для приготовления фармацевтического препарата, предназначенного для применения для лечения такого заболевания, способ лечения такого заболевания и фармацевтический препарат, предназначенный для лечения указанного заболевания. Соединения описываются формулой Iв которой обозначения являются такими, как определено в описании. Эти соединения ингибируют, например, JAK2 и JAK3.
EA200900388A 2006-09-15 2007-09-13 Бензоксазолы и оксазолопиридины, применимые в качестве ингибиторов киназ janus EA200900388A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06120733A EP1900729A1 (en) 2006-09-15 2006-09-15 Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors
PCT/EP2007/007983 WO2008031594A1 (en) 2006-09-15 2007-09-13 Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors

Publications (1)

Publication Number Publication Date
EA200900388A1 true EA200900388A1 (ru) 2009-08-28

Family

ID=37717673

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900388A EA200900388A1 (ru) 2006-09-15 2007-09-13 Бензоксазолы и оксазолопиридины, применимые в качестве ингибиторов киназ janus

Country Status (30)

Country Link
US (1) US8629168B2 (ru)
EP (2) EP1900729A1 (ru)
JP (1) JP5325105B2 (ru)
KR (1) KR20090064389A (ru)
CN (1) CN101516860B (ru)
AR (1) AR062786A1 (ru)
AT (1) ATE532774T1 (ru)
AU (1) AU2007296916B2 (ru)
BR (1) BRPI0716841A2 (ru)
CA (1) CA2660987A1 (ru)
CL (1) CL2007002669A1 (ru)
CO (1) CO6150142A2 (ru)
CR (1) CR10639A (ru)
EA (1) EA200900388A1 (ru)
ES (1) ES2377148T3 (ru)
GT (1) GT200900056A (ru)
IL (1) IL196860A0 (ru)
MA (1) MA30723B1 (ru)
MX (1) MX2009002812A (ru)
NO (1) NO20091469L (ru)
PA (1) PA8748101A1 (ru)
PE (1) PE20080842A1 (ru)
PL (1) PL2066647T3 (ru)
PT (1) PT2066647E (ru)
SM (1) SMP200900023B (ru)
TN (1) TN2009000070A1 (ru)
TW (1) TW200819444A (ru)
UY (1) UY30587A1 (ru)
WO (1) WO2008031594A1 (ru)
ZA (1) ZA200900477B (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2609004C2 (ru) * 2011-07-07 2017-01-30 Санофи Производные карбоновых кислот с оксазоло[4,5-с]пиридиновым циклом
RU2609002C2 (ru) * 2011-07-07 2017-01-30 Санофи ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ С ОКСАЗОЛО[5,4-b] ПИРИДИНОВЫМ КОЛЬЦОМ

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
JP5788316B2 (ja) 2008-07-08 2015-09-30 インテリカイン， エルエルシー キナーゼインヒビターおよび使用方法
EP2583720A1 (en) * 2008-07-15 2013-04-24 Sanofi Oxazolopyrimidines as Edg-1 receptor agonists
EP2323978A1 (en) * 2008-08-12 2011-05-25 Takeda Pharmaceutical Company Limited Amide compound
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
MX2011005621A (es) 2008-11-28 2011-06-20 Kowa Co Derivado de piridin-3-carboxiamida.
JPWO2011078360A1 (ja) 2009-12-24 2013-05-09 武田薬品工業株式会社 アミド化合物
UY33176A (es) * 2010-01-13 2011-08-31 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2, 5, 7.
AR085397A1 (es) 2011-02-23 2013-09-25 Intellikine Inc Combinacion de inhibidores de quinasa y sus usos
CN103102359B (zh) * 2011-11-15 2016-11-09 江苏先声药业有限公司 嘧啶类化合物及其应用
EP2785184B1 (en) 2011-11-30 2020-06-10 Emory University Compositions comprising jak inhibitors and haart drugs for use in the prevention or treatment of hiv
WO2014075318A1 (zh) * 2012-11-19 2014-05-22 江苏先声药业有限公司 嘧啶类化合物及其应用
CN105209042B (zh) 2013-03-22 2019-03-08 米伦纽姆医药公司 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
CN103664759A (zh) * 2013-12-06 2014-03-26 常熟市联创化学有限公司 一种3-羟基-2-硝基吡啶的制备方法
BR112016017993A2 (pt) 2014-02-03 2017-08-08 Quadriga Biosciences Inc Gama-aminoácidos beta-substituídos e análogos como agentes quimioterapêuticos
CA2938571C (en) 2014-02-03 2020-12-22 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
WO2016047678A1 (ja) * 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
AR105592A1 (es) 2015-08-03 2017-10-18 Quadriga Biosciences Inc b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS
TW202307005A (zh) 2021-05-28 2023-02-16 美商邊際分析公司 以核醣體蛋白質S6激酶α-1 (RSK1)及核醣體蛋白質S6激酶α-3 (RSK2)之調節劑治療神經病症之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05351B1 (et) * 1999-12-10 2010-10-15 Pfizer Products Inc. Prrolo[2,3-d]primidiinhendid
SE0301373D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
GB0402140D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
EP1674467A1 (en) * 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
WO2007025897A2 (en) * 2005-09-02 2007-03-08 F. Hoffmann-La Roche Ag Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives
KR20090031787A (ko) * 2006-07-21 2009-03-27 노파르티스 아게 Ｊａｋ 키나제 억제제로서의 ２,４-디(아릴아미노)-피리미딘-５-카르복스아미드 화합물

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2609004C2 (ru) * 2011-07-07 2017-01-30 Санофи Производные карбоновых кислот с оксазоло[4,5-с]пиридиновым циклом
RU2609002C2 (ru) * 2011-07-07 2017-01-30 Санофи ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ С ОКСАЗОЛО[5,4-b] ПИРИДИНОВЫМ КОЛЬЦОМ

Also Published As

Publication number Publication date
CO6150142A2 (es) 2010-04-20
CA2660987A1 (en) 2008-03-20
CR10639A (es) 2009-07-03
TN2009000070A1 (en) 2010-08-19
CN101516860A (zh) 2009-08-26
US8629168B2 (en) 2014-01-14
TW200819444A (en) 2008-05-01
ES2377148T3 (es) 2012-03-22
KR20090064389A (ko) 2009-06-18
ATE532774T1 (de) 2011-11-15
SMP200900023B (it) 2009-07-14
PE20080842A1 (es) 2008-08-11
CN101516860B (zh) 2012-06-27
SMAP200900023A (it) 2009-05-11
US20100009978A1 (en) 2010-01-14
JP2010503629A (ja) 2010-02-04
EP1900729A1 (en) 2008-03-19
CL2007002669A1 (es) 2008-05-09
MX2009002812A (es) 2009-03-31
ZA200900477B (en) 2010-01-27
NO20091469L (no) 2009-04-15
BRPI0716841A2 (pt) 2013-10-01
GT200900056A (es) 2011-11-08
IL196860A0 (en) 2009-11-18
EP2066647B1 (en) 2011-11-09
WO2008031594A1 (en) 2008-03-20
PT2066647E (pt) 2012-01-17
AU2007296916A1 (en) 2008-03-20
UY30587A1 (es) 2008-05-02
MA30723B1 (fr) 2009-09-01
EP2066647A1 (en) 2009-06-10
AU2007296916B2 (en) 2011-10-06
PL2066647T3 (pl) 2012-04-30
PA8748101A1 (es) 2009-08-26
AR062786A1 (es) 2008-12-03
JP5325105B2 (ja) 2013-10-23

Similar Documents

Publication Publication Date Title
EA200900388A1 (ru) Бензоксазолы и оксазолопиридины, применимые в качестве ингибиторов киназ janus
EA201001365A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДУЕМОГО C-МЕТ ТИРОЗИНКИНАЗОЙ
BRPI0407834A (pt) composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
EA201000552A1 (ru) Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
DE60028740D1 (de) Phthalazinderivate zur behandlung von entzündlicher erkrankungen
BRPI0513750A (pt) 2-fenilamino-benzamidas-5-substituìdas como inibidoras de mek
BRPI0513565A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir uma atividade de proteìna cinase, e para tratar um paciente tendo uma condição que é mediada por atividade de proteìna cinase, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
EA200870373A1 (ru) Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ
BRPI0416212A (pt) derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
BRPI0415395A (pt) composto, métodos para inibir a atividade da proteìna quinase e para tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase, e, composição
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
TW200615266A (en) Organic compounds
EA200900733A1 (ru) ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНА, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И БОЛЕЗНЕЙ, СВЯЗАННЫХ С АНГИОГЕНЕЗОМ
SE0202462D0 (sv) Novel use
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
ATE453646T1 (de) 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren
SE0202429D0 (sv) Novel Compounds
BRPI0514390A (pt) enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica
DE602004020685D1 (de) Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3-cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i-epsilon
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
ATE444069T1 (de) Chinolin-derivate zur behandlung von mglur5- rezeptor-vermittelten erkrankungen